Pelthos Therapeutics PTHS
NYSE PTHS
$25.51 -1.15 (-4.31%)
At close: Aug 21, 2026 · 4:00 PM EDT

Pelthos Therapeutics (PTHS) Cost of Revenue (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly Cost of Revenue of $1.7 million for Q4 2025, down 27.81% quarter-over-quarter from $2.3 million in Q3 2025.

Pelthos Therapeutics (PTHS) Cost of Revenue (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' Cost of Revenue history runs 1 years deep, the most recent figure standing at $1.7 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 489.20 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 360.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 145.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 93.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 174.53 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 298.26 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 387.98 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 67.21 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Pelthos Therapeutics 91.09 Mn 66.53 Mn 21.23 Mn 5.28 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 5.28 Mn
Jun 30, 2026 5.28 Mn
Dec 31, 2025 1.67 Mn
Dec 31, 2025 1.67 Mn
Sep 30, 2025 2.32 Mn
Sep 30, 2025 2.32 Mn